Intellia Therapeutics to Present at March Investor Healthcare Conferences

CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key March investor healthcare conferences, including the Cowen and Company 37th Annual Health Care Conference, the Goldman Sachs Third Annual Innovation Symposium, and the Oppenheimer 27th Annual Healthcare Conference.

Details of the upcoming presentations are as follows:

Wednesday, March 8th Cowen and Company 37th Annual Health Care ConferenceWho: Nessan Bermingham, Ph.D., chief executive officer & founderLocation: Boston, MassachusettsPresentation Time: 8:40 am ET

Wednesday, March 15thThe Goldman Sachs Third Annual Innovation SymposiumGene Editing and CRISPR PanelWho: Nessan Bermingham, Ph.D., chief executive officer & founderLocation: New York, New YorkPanel Time: 10:15 am ET

Wednesday, March 22nd The Oppenheimer 27th Annual Healthcare ConferenceWho: John Leonard, M.D., executive vice president, R&D Location: New York, New YorkPresentation Time: 2:45 pm ET

Individuals may access the presentations for available conferences via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. When available, replays of these webcasts will be available on the site for 90 days following the live events.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 (857) 706-1071
[email protected]

Investor Contact:
Graeme Bell
Chief Financial Officer
+1 (857) 706-1081
[email protected]

You May Also Be Interested In

• CHIME Announces New Board Members and Officers, Strengthening Leadership Through 2029
• EPAS Responds to Withdrawal of Jeffrey Anderson’s ICAO Council Nomination
• Back to a Routine with The Charming Taste of Europe: Quality European Products for Everyday Cooking